Helixmith Co., Ltd is a gene therapy company with over 20 years experience developing new and innovative biopharmaceuticals to tackle previously untreated diseases. The company is based in Seoul and San Diego, publicly traded in the Korean stock market. Currently, the company is actively focusing on developing the proprietary plasmid DNA-based drug Engensis (VM202) at various clinical stages in the U.S., Korea, and China for neurological and cardiovascular diseases including, but not limited to, diabetic peripheral neuropathy (DPN), diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), claudication, coronary artery disease (CAD), and Charcot-Marie-Tooth disease (CMT). The company also has an early phase pipeline in AAV-based gene therapy for neuromuscular diseases and CAR-T cell therapy for solid tumors.
Company HQ State:
Company HQ Country:
Korea - South Korea
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):